Literature DB >> 23127271

Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up.

Agnieszka Jurecka1, Jolanta Marucha, Elżbieta Jurkiewicz, Agnieszka Różdżyńska-Świątkowska, Anna Tylki-Szymańska.   

Abstract

We present the 6.5-year follow-up of a boy with Scheie syndrome whose therapy was initiated at age 2.5 years. Detailed anthropometric features, echocardiography, ophthalmologic and audiologic examinations, psychologic tests, joint range of motion, skeletal radiographs, ultrasound studies of liver and spleen volumes, urinary glycosaminoglycans, and antibodies were documented. After 6.5 years of enzyme replacement therapy, the patient experienced a decline in overall status, and the disease progressed significantly despite treatment. The patient's height at age 9 was equal to that at age 6. The patient developed heart insufficiency and a deterioration of airway flow. The patient's intelligence quotient remained unchanged, i.e., at the average level of 86 on the Terman-Merill Scale. Magnetic resonance imaging revealed cervical spinal canal stenosis and marked spinal cord compression with myelopathy. A worsening of carpal tunnel syndrome was also evident. Ophthalmologic evaluation revealed increased central corneal thickness and intraocular pressure. In audiologic assessment, the patient's results were similar to those after 3 years of treatment. The only benefit involved temporarily improved passive and active shoulder flexion. Overall, the benefit of enzyme replacement therapy with laronidase on Scheie syndrome appeared minimal.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23127271     DOI: 10.1016/j.pediatrneurol.2012.08.010

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  4 in total

1.  12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.

Authors:  Orazio Gabrielli; Lorne A Clarke; Anna Ficcadenti; Lucia Santoro; Lucia Zampini; Nicola Volpi; Giovanni V Coppa
Journal:  BMC Med Genet       Date:  2016-03-10       Impact factor: 2.103

2.  The Complexity of Pain Management in Children Affected by Mucopolysaccharidoses.

Authors:  Sabrina Congedi; Chiara Di Pede; Maurizio Scarpa; Angelica Rampazzo; Franca Benini
Journal:  Case Rep Pediatr       Date:  2017-04-03

Review 3.  Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.

Authors:  Alícia Dorneles Dornelles; Osvaldo Artigalás; André Anjos da Silva; Dora Lucia Vallejo Ardila; Taciane Alegra; Tiago Veiga Pereira; Filippo Pinto E Vairo; Ida Vanessa Doederlein Schwartz
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240

Review 4.  Pain in Mucopolysaccharidoses: Analysis of the Problem and Possible Treatments.

Authors:  Sabrina Congedi; Marcello Orzalesi; Chiara Di Pede; Franca Benini
Journal:  Int J Mol Sci       Date:  2018-10-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.